Syros Pharmaceuticals Inc. (NASDAQ:SYRS) has a beta of 1.98. The stock’s Relative Strength Index (RSI) is 76.98, with weekly volatility at 13.24% and ATR at 1.14. The SYRS stock’s 52-week price range has touched low of $4.26 and a $14.69 high. Its shares traded higher over the last trading session, gaining 9.01% on 12/22/20. The shares fell to a low of $13.00 before closing at $14.03. Intraday shares traded counted 1.42 million, which was -154.79% lower than its 30-day average trading volume of 557.70K. SYRS’s previous close was $12.87 while the outstanding shares total 45.78M.
Investors have identified the Biotechnology company Syros Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $582.67 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Syros Pharmaceuticals Inc. (SYRS) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 98.56 million total, with 28.06 million as their total liabilities.
SYRS were able to record -30.75 million as free cash flow during the Q3 2020 quarter of the year, this saw their quarterly net cash flow reduce by 51.4 million. In cash movements, the company had a total of -27.44 million as operating cash flow.
Potential earnings growth for Syros Pharmaceuticals Inc. (SYRS)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the Q3 2020 quarter of the year, Syros Pharmaceuticals Inc. recorded a total of 3.83 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 85.42% coming in sequential stages and their sales for the Q3 2020 quarter increasing by 16.72%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 3.83 million trying to sell their products during the last quarter, with the result yielding a gross income of 22.82 million. This allows shareholders to hold on to 45.78M with the recently reported earning now reading -0.43 cents per share. This is a figure that compared to analyst’s prediction for their Q3 2020 (-0.43 cents a share).
Having a look at the company’s valuation, the company is expected to record -1.74 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on SYRS sounds very interesting.
Is the stock of SYRS attractive?
In related news, Director, Young Richard A sold 5,357 shares of the company’s stock in a transaction that recorded on Nov 17. The sale was performed at an average price of 8.75, for a total value of 46,874. As the sale deal closes, the Director, Young Richard A now sold 633 shares of the company’s stock, valued at 5,684. Also, Director, Young Richard A sold 5,673 shares of the company’s stock in a deal that was recorded on Oct 19. The shares were price at an average price of 8.75 per share, with a total market value of 49,639. Following this completion of acquisition, the Director, Young Richard A now holds 317 shares of the company’s stock, valued at 2,774. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.70%.
8 out of 9 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on Syros Pharmaceuticals Inc.. 0 analysts has assigned a Sell rating on the SYRS stock. The 12-month mean consensus price target for the company’s shares has been set at $15.88.